EU Flag

Glycotope GmbH is project based co-funded by the European Fund for Regional Development [EFRE].

 Logo YUMABFrauenhofer
Biopharmaceuticals Pipeline Glycotope’s mature biopharmaceuticals pipeline Find out more
Biopharmaceuticals Services Glycotope’s unique development expertise Find out more

Using world-leading glycobiology expertise to improve outcomes for patients

About
An introduction to our company and experienced leadership
Technology
Learn how we are leveraging our proprietary technologies to drive innovation
Gatipotuzumab
Our first-in-class antibody against a tumor-specific carbohydrate-protein epitope
Careers
Join us
News
30. Apr
2021
Glycotope Announces Poster Presentations at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

Glycotope Announces Poster Presentations at the 2021 American Society of Clinical Oncology (ASCO) Virtual […]

17. Dec
2020
Glycotope announces licensing agreement with ONK Therapeutics for humanized GlycoBody targeting TA-MUC1

Glycotope announces licensing agreement with ONK Therapeutics for humanized GlycoBody targeting TA-MUC1 GlycoBody to […]

See All News
Events
See All Events